We are live on ! Find out more
URGN icon

UroGen Pharma
URGN

86 hedge funds and large institutions have $473M invested in UroGen Pharma in 2019 Q4 according to their latest regulatory filings, with 10 funds opening new positions, 40 increasing their positions, 24 reducing their positions, and 8 closing their positions.

New
Increased
Maintained
Reduced
Closed

67% more repeat investments, than reductions

Existing positions increased: 40 | Existing positions reduced: 24

36% more capital invested

Capital invested by funds: $347M → $473M (+$126M)

25% more first-time investments, than exits

New positions opened: 10 | Existing positions closed: 8

2% more funds holding

Funds holding: 84 → 86 (+2)

0% more funds holding in top 10

Funds holding in top 10: 2 → 2 (0)

6% less call options, than puts

Call options by funds: $8.04M | Put options by funds: $8.55M

2.09% less ownership

Funds ownership: 69.69% → 67.6% (-2.1%)

Holders
86
Holders Change
+2
Holders Change %
+2.38%
% of All Funds
1.69%
Holding in Top 10
2
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.04%
New
10
Increased
40
Reduced
24
Closed
8
Calls
$8.04M
Puts
$8.55M
Net Calls
-$511K
Net Calls Change
+$119K

Top Buyers

Rank Fund Capital Flow
1
Point72 Asset Management
Point72 Asset Management
Connecticut
+$4.48M
2
PF
Phoenix Financial
Israel
+$4.2M
3
JP Morgan Chase
JP Morgan Chase
New York
+$3.41M
4
VOYA Investment Management
VOYA Investment Management
Georgia
+$3.28M
5
WCM
Wildcat Capital Management
New York
+$2.72M

Top Sellers

Rank Fund Capital Flow
1
CI
Clal Insurance
Israel
-$14M
2
SFM
Sphera Funds Management
Israel
-$8M
3
Fidelity Investments
Fidelity Investments
Massachusetts
-$7.47M
4
PM
Prosight Management
Texas
-$2.94M
5
Wellington Management Group
Wellington Management Group
Massachusetts
-$2.62M
Name Holding Trade Value Shares
Change 		Change in
Stake
SG Americas Securities
26
SG Americas Securities
New York
$1.68M +$16K +585 +1%
Bank of New York Mellon
27
Bank of New York Mellon
New York
$1.61M +$54.4K +1,992 +4%
California State Teachers Retirement System (CalSTRS)
28
California State Teachers Retirement System (CalSTRS)
California
$1.56M +$1.31K +48 +0.1%
AA
29
ALPS Advisors
Colorado
$1.42M +$23.8K +871 +2%
Charles Schwab
30
Charles Schwab
California
$1.35M +$31.9K +1,169 +3%
California Public Employees Retirement System
31
California Public Employees Retirement System
California
$1.2M +$450K +16,500 +85%
Victory Capital Management
32
Victory Capital Management
Texas
$1.15M +$39.6K +1,451 +4%
Swiss National Bank
33
Swiss National Bank
Switzerland
$1.14M +$10.9K +400 +1%
Jane Street
34
Jane Street
New York
$1.06M +$866K +31,719 New
State of Wisconsin Investment Board
35
State of Wisconsin Investment Board
Wisconsin
$938K – – –
Group One Trading
36
Group One Trading
Illinois
$938K +$767K +28,096 New
Morgan Stanley
37
Morgan Stanley
New York
$935K +$487K +17,832 +175%
AS
38
Altshuler Shaham
Israel
$873K – – –
RhumbLine Advisers
39
RhumbLine Advisers
Massachusetts
$781K +$38.1K +1,395 +6%
AllianceBernstein
40
AllianceBernstein
Tennessee
$731K – – –
EMG
41
ETF Managers Group
New Jersey
$731K +$44.7K +1,638 +8%
UBS Group
42
UBS Group
Switzerland
$730K +$215K +7,866 +56%
PPA
43
Parametric Portfolio Associates
Washington
$699K +$33.8K +1,237 +6%
Barclays
44
Barclays
United Kingdom
$660K +$267K +9,799 +98%
CBA
45
Coastal Bridge Advisors
Connecticut
$657K +$54.6K +2,000 +11%
BHB
46
Bank Hapoalim BM
Israel
$569K -$278K -10,175 -37%
UBS AM
47
UBS AM
Illinois
$547K +$448K +16,401 New
New York State Common Retirement Fund
48
New York State Common Retirement Fund
New York
$544K -$79.2K -2,900 -15%
AIM
49
ARK Investment Management
Florida
$535K +$48.9K +1,790 +13%
CI
50
Clal Insurance
Israel
$529K -$14M -511,722 -97%
1
2
3 4

URGN Hedge Fund Activity: Q4 2019 in Review

86 of the 5,075 institutional investors tracked by Wall St. Rank reported a position in UroGen Pharma (URGN) for Q4 2019, worth a combined $473M — up 36% from $347M a quarter earlier.

Buyers outnumbered sellers: 10 funds opened new URGN positions and 8 closed out — a net gain of 2 holders — while 40 added to existing stakes and 24 trimmed.

The largest buyer was Point72 Asset Management, adding an estimated $4.48M. The largest seller was Clal Insurance, cutting an estimated $14M.

  • 86 institutional investors held UroGen Pharma (URGN) as of Q4 2019, up from 84 in Q3 2019.
  • Funds reported $473M of UroGen Pharma stock for Q4 2019, up 36% quarter-over-quarter.
  • 10 funds opened new UroGen Pharma positions in Q4 2019 and 8 closed out, a net change of +2 holders.
  • The largest UroGen Pharma buyer in Q4 2019 was Point72 Asset Management, an estimated $4.48M added.
  • The largest UroGen Pharma seller in Q4 2019 was Clal Insurance, an estimated $14M sold.

Based on aggregated 13F filings for Q4 2019.